---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000066"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:00:58.641551+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy

## Summary
- Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.
- Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.
- Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.
- Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy.

## SEC filing metadata
- accession: 0001724521-25-000066
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/0001724521-25-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/rcus-20250601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000066
- JSON: https://secwatch.observer/filing/0001724521-25-000066.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.